February 19, 2019 07:23 AM EST
R&D

Throw­ing in the tow­el, trou­bled an­tibi­ot­ic mak­er Ar­a­digm files for Chap­ter 11

Amber Tong

One year ago, a cash-strapped Ar­a­digm let go of its CEO, CFO and CMO in a fi­nal at­tempt to re­vive the com­pa­ny fol­low­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

A service from the Financial Times